 NEW YORK, March 03, 2022 GLOBE NEWSWIRE -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T iNKT cell therapies to treat cancer and other immune-mediated diseases, announced it will release its independent fourth quarter and full year 2021 financial results and a business update before the market opens on Friday, March 18, 2022. 